Expression of CXCR4 in Patients With Systemic Lupus Erythematosus

Study of CD184 in Systemic Lupus Erythematosus

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04799730

Enrollment

100

Registered

2021-03-16

Start date

2021-05-31

Completion date

2022-05-31

Last updated

2021-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Keywords

CXCR4,CD184,Flow cytometry ,Systemic lupus erythematosus

Brief summary

The objective of this study is to estimate the possible role of CD184 in the pathogenesis of SLE; comparing its level among SLE cases to healthy controls.

Detailed description

Detection of CXCR4 (CD184) expression on CD19+ B cells by flow cytometry in patients of SLE, comparing its level in the development of lupus activity and pathogenic process of SLE internal organ involvement/ mucocutaneus and/or musculoskeletal involvement. Identify this correlation will be useful for clarifying other accessory factors to improve the diagnosis, better treatment strategy, follow up as well as prognosis for these patients

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

16 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Confirmed SLE patients diagnosed and fulfilled the SLE classification criteria according to the 2019 ACR/EULAR classification criteria for SLE (Aringer et al., 2019) * Willing and agreed to be included in the study.

Exclusion criteria

* Childhood SLE. * SLE-patients will refuse to consent to this study. * Other autoimmune diseases. * Known or suspected malignancies, especially B cell lymphoma.

Design outcomes

Primary

Measure	Time frame	Description
changes in the expression of CD184(CXCR4) expression in circulating B cells	6 months	Flow cytometry analysis of chemokine receptor (CXCR4):Human peripheral-blood mononuclear cells (PBMCs) labeling with CXCR4 antibody will be performed in the same day after taking blood samples and subsequent measurement of the CXCR4 mean fluorescence intensity (MFI) by flow cytometry. MFI of the anti-chemokine receptor (CXCR4) staining will be calculated according to statistical thresholds set in reference to staining with negative control antibodies. The patient's CXCR4 on CD19+ B cells expression or mean MFI will be further compared to the MFI of the simultaneously performed age-matched controls samples and other subgroups of SLE patients.

Contacts

Primary ContactAsmaa A Ibrahim, Master

smaibrahim2019@gmail.com01032138809

Backup ContactShereen Philip Aziz, Professor

01033386104

Outcome results